Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abridged melarsoprol schedule for late-stage T. b. rhodesiense sleeping sickness
ISRCTN40537886Phase 2Completed
- Sponsor
- Swiss Tropical and Public Health Institute
- Start
- May 2006
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of melarsoprol and suramin in African trypanosomiasis (HAT) (2 arms), sponsored by Swiss Tropical and Public Health Institute. Primary endpoints: Parasitological and clinical cure at 24 hours after treatment and Safety through end of treatment and 30 days post-treatment. Started May 2006; status: completed.
02
Drugs
melarsoprolsuramin
03
Conditions
African trypanosomiasis (HAT)
Beyond the preview
Go deeper on ISRCTN40537886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40537886.